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Age of people with type 2 diabetes and the risk of dying 
following SARS- CoV- 2 infection
Letter to the Editor
In 2020, the whole world has been challenged by the SARS- CoV- 2 
virus (Coronavirus- 19).1 Following coronavirus- 19 infection people 
with diabetes are at higher risk than those who do not have diabetes, 
of becoming very unwell and in some cases dying.2- 4 Notably, Barron 
et al 4 reported an odds ratio (OR) of 2.03 (95% CI 1.97- 2.09) for in- 
hospital coronavirus- 19- related death in people with type 2 diabetes 
(T2DM). A body of work is emerging which is beginning to explain 
why people with diabetes are more likely to become seriously unwell 
following a coronavirus- 19 infection. However, much of the detail 
remains to be determined.3
For people with diabetes, 2020 has been a very difficult year, 
with the awareness that their condition puts them at an increased 
risk of becoming very seriously unwell/dying following coronavi-
rus- 19 infection. It is, therefore, critical to determine all the factors 
that put any person with diabetes at an increased risk of a serious 
outcome after contracting a coronavirus- 19 infection.
In one area of the United Kingdom (Salford) over the period of 
March- October 2020, we examined the potential risk factors relat-
ing to mortality in people with T2DM, who were confirmed as being 
coronavirus- 19 positive. We examined health records for a repre-
sentative sample of 308 T2DM people who were confirmed to be 
infected with coronavirus- 19.
All data for this study were fully anonymised prior to analysis. 
The data were only released after the approval of the project by the 
Salford Integrated Record (SIR) Board.
Of these 56 people died, with the peak mortality rates seen in 
the months of April/May 2020. All patient data were fully anony-
mised prior to analysis.
Overall deaths for T2DM individuals living in Salford were 
100% higher in March, 220% higher in April and 34% higher in May 
2020 compared with the previous 5- year average monthly mortal-
ity rates for people with T2DM. Those who died following a con-
firmed coronavirus- 19 infection were significantly older than those 
who survived (age ± 95% confidence Interval (CI)) at 82.8 ± 10.3 vs 
70.7 ± 14.8 years (P <.001). In multivariate logistic regression analy-
sis, only age (Odds ratio (OR) (95% CI)) 1.07 (1.02- 1.12) was the pre-
dictive of death following coronavirus- 19 infection, independent of 
gender, glycosylated haemoglobin (HbA1c), diastolic blood pressure, 
body mass index, serum creatinine, serum cholesterol, smoking sta-
tus, and urine albumin/creatinine ratio. None of the other variables 
(than age) were statistically significant.
We were not able to include ethnicity in the analysis, as the sam-
ple included only a small number of people of non- Caucasian ethnic 
origin.
This analysis highlights the fact that age outweighs many other 
factors in people with T2DM in relation to mortality from the coro-
navirus- 19 once infected, as previously proposed by McCullough 
et al5 in a paper advocating that age should be an important feature 
in risk stratification for early ambulatory treatment in the context of a 
Sars- Cov- 2 (Covid- 19) infection. The age factor should, therefore, be 
taken into account in relation to the vaccination programme against 
the coronavirus- 19 in people with T2DM in the United Kingdom and 
elsewhere, while emphasising as always, support for concordance with 
lifestyle and pharmacological management in order to optimise the 
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